Ghana, Kenya and Malawi will begin piloting the injectable vaccine next year on hundreds of thousands of young children, who have been at the highest risk of death.
Malaria remains one of the world’s most stubborn health challenges, infecting more than 200 million people every year and killing about half a million.
The vaccine, which has partial effectiveness, has the potential to save tens of thousands of lives if used with existing measures, WHO regional director for Africa, Dr Matshidiso Moeti, said in a statement. The challenge is whether impoverished countries can deliver the required four doses of the vaccine for each child.
Malaria remains one of the world’s most stubborn health challenges, infecting more than 200 million people every year and killing about half a million, most of them children, in Africa. Bed netting and insecticides are the chief protection.
Sub-Saharan Africa is hardest hit by the disease, with about 90% of the world’s cases in 2015. Malaria spreads when a mosquito bites someone already infected, sucks up blood and parasites, and then bites another person.
The vaccine will be tested on children five to 17 months old to see whether its protective effects shown so far in clinical trials can hold up under real-life conditions. At least 1,20,000 children in each of the three countries will receive the vaccine, which has taken decades of work and hundreds of millions of dollars to develop.
Kenya, Ghana and Malawi were chosen for the vaccine pilot because all have strong prevention and vaccination programs but continue to have high numbers of malaria cases, the WHO said. The countries will deliver the vaccine through their existing vaccination programs.
The WHO is hoping to wipe out malaria by 2040 despite increasing resistance problems to both drugs and insecticides used to kill mosquitoes.
“The slow progress in this field is astonishing, given that malaria has been around for millennia and has been a major force for human evolutionary selection, shaping the genetic profiles of African populations,” Kathryn Maitland, professor of tropical pediatric infectious diseases at Imperial College London, wrote in the New England Journal of Medicine in December. “Contrast this pace of change with our progress in the treatment of HIV, a disease a little more than three decades old.”
The malaria vaccine has been developed by pharmaceutical company GlaxoSmithKline, and the $49 million for the first phase of the pilot is being funded by the global vaccine alliance GAVI, UNITAID and Global Fund to Fight AIDS, Tuberculosis and Malaria.